In July 2024, Triastek had announced that it has entered into a research collaboration and platform technology license agreement with BioNTech SE, a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. Under the agreement, the companies will develop RNA therapeutics for oral delivery based on 3D printing technology. The collaboration aims to provide groundbreaking therapies to address unmet medical needs in an easy to administer oral formulation.

In March 2023, Triastek had partnered with Boehringer Ingelheim China to explore the application of Triastek's proprietary Melt Extrusion Deposition (MED®) 3D printing technology in accelerating the development of the dosage form for new chemical entity (NCE). Triastek deploys its MED® technology to create multiple prototypes of NCE by exploring different dose designs and drug release behaviors at speed, ultimately accelerating the R&D cycle and increasing product development success rates.